GlassScriptPhysician profile
Erron David Pujol
NPI 1528019726
$3,994.12
in general payments reported to CMS, 2019-2025
36 companies · $598 in 2025
The $598 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,262 · 2022: $738 · 2023: $897 · 2024: $499 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683 · Travel and Lodging: $291 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.18 |
| Travel and Lodging | $290.94 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,760.52 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $420.44 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Amgen INC. | $268.52 | 2021-2022 | |
| Lilly USA, LLC | $179.45 | 2021-2025 | Zepbound |
| Novo Nordisk INC | $128.30 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $111.01 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $108.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.70 | 2021-2025 | Jardiance |
| Pfizer INC. | $83.80 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $81.21 | 2021 | |
| Merck Sharp & Dohme LLC | $70.06 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $65.01 | 2021-2023 | Recorlev |
| Sanofi-Aventis U.S. LLC | $55.67 | 2023-2025 | |
| Amarin Pharma, INC. | $53.86 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $52.02 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $37.05 | 2021 | |
| Clarus Therapeutics INC. | $35.54 | 2021 | |
| Ucb, INC. | $34.10 | 2021 | |
| Mallinckrodt Hospital Products INC. | $32.38 | 2021 | |
| Aurinia Pharma U.S., INC. | $32.05 | 2021 | |
| Chiesi USA, INC. | $24.74 | 2024 | Mycapssa |
| Abbott Laboratories | $24.56 | 2025 | Freestyle Libre 3 |
| Sandoz INC. | $22.16 | 2023 | Hyrimoz |
| Celltrion USA INC. | $19.97 | 2023 | Yuflyma |
| Ardelyx, INC. | $19.67 | 2025 | Ibsrela |
| Ibsa Pharma INC. | $18.57 | 2021 | |
| Axsome Therapeutics, INC. | $18.57 | 2025 | Auvelity |
| Acella Pharmaceuticals, LLC | $18.25 | 2023 | NP Thyroid 60 |
| Teva Pharmaceuticals USA, INC. | $17.76 | 2025 | Uzedy |
| Radius Health, INC. | $17.47 | 2021 | |
| Insulet Corporation | $17.29 | 2024 | Omnipod |
| Corcept Therapeutics | $15.97 | 2025 | Korlym |
| Horizon Therapeutics Plc | $15.70 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.04 | 2021 | |
| Vivus LLC | $10.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erron Pujol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.